Additional 7.5 million Americans covered under Biden's plan The Biden Administration has announced that it wants to expand <a ...

Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Accelerator™ Drug Development, intended to serve biotechs and pharmas.

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster ... feedback on ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. The regulatory reprimand ...

The new plant will be one of the largest manufacturing investments in Novo Nordisk’s history and will add 1.4 million sq ft of production space for aseptic manufacturing and finished production ...

Novo Nordisk has become Europe’s most valuable company due to soaring demand for its weight-loss-aiding drugs Wegovy, Semaglutide, and Ozempic. But as the effective backbone of the Danish ...

Novo Nordisk has been on a yearslong push to bolster manufacturing capacity for its ... down $4.1 billion to build a second fill-finish plant at its massive campus in Clayton, North Carolina.

Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity ...

Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call ... Capital expenditure for property, plant and equipment was DKK 31.1 billion compared to DKK 16.4 billion in 2023.

The company, headquartered in the key swing state of Pennsylvania, has announced the creation of 330 jobs in a significant ...

Novo Nordisk remains the market leader in international operations with a GLP-1 diabetes value market share of almost 67%. Ozempic is still the GLP-1 diabetes market leader with 44% market share.